This site is intended for healthcare professionals

Alexion announces positive results from phase III study of Ultomiris.

Read time: 3 mins
Last updated:16th Jul 2021
Published:16th Jul 2021
Alexion Pharmaceuticals, Inc. announced positive topline results from a Phase III study evaluating the safety and efficacy of Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis (gMG).
Condition: Myasthenia Gravis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest